Autoimmune Diseases

Treatments for Autoimmune Diseases

Genotype Marker​

Scleroderma is a chronic autoimmune disease in which the skin and connective tissue tightens and hardens. Median survival from diagnosis is approximately 11 years. Patients experience a deteriorating quality of life and typically die from complications of the disease.   There is no cure or effective treatment for the disease. 
Biomarkers enable physicians to choose treatments that will work in a specific patient.  In addition there is a quest to use biomarkers to identify patients who will have an adverse reaction to a treatment.  This is often referred to as “personalized medicine.”  

Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of your joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.

Aut​oImmune Disease Treatments

arGentis™ Pharmaceuticals, LLS is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU.

The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc.

Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Pharmaceuticals, LLC
Rheumatoid Arthritis